|
|
Press Releases
| All Releases |
|---|
 |
Osiris Therapeutics Reports Third Quarter 2009 Financial Results
11-04-09
26.6 KB
|
| |
COLUMBIA, Md., Nov 04, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, cardiovascular and orthopedic areas,
announced today its financial results for the third quart...
|
|
Osiris Therapeutics Achieves $15 Million Milestone Payment
11-03-09
12.5 KB
|
| |
COLUMBIA, Md., Nov 03, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ: OSIR), today announced that the company
has achieved a $15 million milestone payment from NuVasive (NASDAQ:
NUVA) related to the sale of the Osteocel business. Triggering the
payment, NuVasive recently reached $35 million in cumulative ...
|
|
Osiris Therapeutics Announces Third Quarter 2009 Financial Results Conference Call
10-23-09
13.6 KB
|
| |
COLUMBIA, Md., Oct 23, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced that it will
report its financial results for the quarter ended September 30, 2009,
on Wednesday, November 4, 2009. C. Randal Mills, Ph.D., President and
Chief Executive Officer, and Philip R. Jacoby, Jr., Chief Fi...
|
|
Osiris Therapeutics to Present at Fourth Annual JMP Securities Healthcare Focus Conference
09-30-09
11.7 KB
|
| |
COLUMBIA, Md., Sep 30, 2009 (BUSINESS WIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell
therapeutic company focused on developing products to treat medical
conditions in the inflammatory, orthopedic and cardiovascular areas,
announced today that C. Randal Mills, Ph.D., President and Chief
Execut...
|
|
Osiris Therapeutics to Present at ThinkEquity and UBS Conferences
09-11-09
12.5 KB
|
| |
COLUMBIA, Md., Sep 11, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic
company focused on developing products to treat medical conditions in
the inflammatory, orthopedic and cardiovascular areas, announced today
that C. Randal Mills, Ph.D., President and CEO, is sche...
|
|
Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GvHD Trials
09-08-09
18.6 KB
|
| |
COLUMBIA, Md., Sep 08, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary
results for two phase III trials evaluating Prochymal for the treatment
of acute graft versus host disease (GvHD). GvHD, the most common
complication of bone marrow transplantation, is a life-threatenin...
|
|
Osiris Therapeutics Reports Second Quarter 2009 Financial Results
08-06-09
26.1 KB
|
| |
COLUMBIA, Md., Aug 06, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell therapeutic
company focused on developing and marketing products to treat medical
conditions in the inflammatory, cardiovascular and orthopedic areas,
announced today its financial results for the second qua...
|
|
Osiris Therapeutics Creates Biosurgery Division
08-04-09
13.0 KB
|
| |
COLUMBIA, Md., Aug 04, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced the creation of a
new Biosurgery Division focused on developing and marketing high-end
biological products for use in surgical procedures. The company intends
to build on the success of its first generation implanta...
|
|
Osiris Achieves Milestone Payment for Progress Developing Stem Cell Therapy for Type 1 Diabetes
07-28-09
17.6 KB
|
| |
COLUMBIA, Md., Jul 28, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has
achieved a $750,000 milestone payment from the Juvenile
Diabetes Research Foundation (JDRF) for progress made on a Phase II
clinical trial evaluating Prochymal, an adult mesenchymal stem cell
(MS...
|
|
Osiris Therapeutics Announces Second Quarter 2009 Financial Results Conference Call
07-27-09
13.5 KB
|
| |
COLUMBIA, Md., Jul 27, 2009 (BUSINESS WIRE) -- Osiris
Therapeutics, Inc. (NASDAQ:OSIR) today announced that it will report
its financial results for the quarter ended June 30, 2009, on Thursday,
August 6, 2009. C. Randal Mills, Ph.D., President and Chief Executive
Officer, and Richard Hunt, Chief Financial Officer, w...
|
|
|
 |
Stock Information
OSIR - (NASDAQ)
$6.68
+ 0.40
|
11-06-09
4:13 PM ET
Quotes delayed at least 20 minutes. Information provided by eSignal.
|
|
|
|
|
Shareholder Tools
|
|
